MedTrace Logo

Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.

NCT02133118 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16293

Last updated 2015-03-17

No results posted yet for this study

Summary

Next to HbA1c, body weight is regarded as an important surrogate end-point in trials investigating glucose-lowering agents. An increase in weight could contribute to worsening insulin resistance. Differences in weight after starting glucose lowering agents have been described in many randomized controlled trials (RCTs).

With this prospective observational study, weight trajectories after receiving add-on therapy next to metformin are evaluated in primary care patients with good glycaemic control.

Conditions

Interventions

DRUG

individual SUs, insulin, pioglitazone

Sponsors & Collaborators

  • Medical Research Foundation, The Netherlands

    lead OTHER

Principal Investigators

  • G. W.D. Landman, MD PhD · Isala, Diabetes Centre

  • R. Wever, MD · Isala, Diabetes Centre

  • P. R. van Dijk, MD · Isala, Diabetes Centre

  • Nanne Kleefstra, MD PhD · Diabetes Centre, Isala, Zwolle

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02133118 on ClinicalTrials.gov